{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:52:08Z","timestamp":1792169528457,"version":"4.4.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cytogfr.2026.101534","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:49:03Z","timestamp":1791960543000},"page":"101534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interleukin-1\u03b2 as a central driver of inflammation: Mechanistic insight into activation, receptor signaling, and therapeutic inhibition"],"prefix":"10.1016","volume":"92","author":[{"given":"Reetika","family":"Tamang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-6204","authenticated-orcid":false,"given":"Madhulika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2026.101534_bib1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1046\/j.1440-1711.1998.00757.x","article-title":"Cytokines: principles and prospects","volume":"76","author":"Kelso","year":"1998","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41577-019-0131-x","article-title":"Cytokine-mediated communication: a quantitative appraisal of immune complexity","volume":"19","author":"Altan-Bonnet","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02982543","article-title":"Cytokines: past, present, and future","volume":"74","author":"Oppenheim","year":"2001","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib4","doi-asserted-by":"crossref","first-page":"00121","DOI":"10.15406\/moji.2016.04.00121","article-title":"Cytokines and their role in health and disease: a brief overview","volume":"4","author":"Ray","year":"2016","journal-title":"MOJ Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib5","first-page":"S1","article-title":"The IL-1 family and inflammatory diseases","volume":"20","author":"Dinarello","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor \u03b2, and TNF-\u03b1: Receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and Inflammatory Functions of the Interleukin-1 Family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, Inflammation, and Pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int. Anesthesiol. Clin."},{"key":"10.1016\/j.cytogfr.2026.101534_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","article-title":"Cytokine Signaling Modules in Inflammatory Responses","volume":"28","author":"O\u2019Shea","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2026.101534_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL -1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2026.101534_bib12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fimmu.2019.01412","article-title":"Structural Basis of IL-1 Family Cytokine Signaling","volume":"10","author":"Fields","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The Interleukin-1 Family: Back to the Future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2026.101534_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ni.3503","article-title":"Interleukin 1\u03b1 and the inflammatory process","volume":"17","author":"Di Paolo","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cytogfr.2011.10.001","article-title":"Understanding the mechanism of IL-1\u03b2 secretion","volume":"22","author":"Lopez-Castejon","year":"2011","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2007.03441.x","article-title":"The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders","volume":"149","author":"Barksby","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/0008-5472.CAN-06-2956","article-title":"Interleukin-1\u03b2\u2013Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen\u2013Induced Tumors","volume":"67","author":"Krelin","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.101534_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2021.09.004","article-title":"The interleukin-1 cytokine family members: Role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy","volume":"62","author":"Boersma","year":"2021","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cytogfr.2018.11.001","article-title":"Potential roles of IL-1 subfamily members in glycolysis in disease","volume":"44","author":"Tan","year":"2018","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/386190a0","article-title":"Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1\u03b2","volume":"386","author":"Vigers","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2026.101534_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/386194a0","article-title":"A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist","volume":"386","author":"Schreuder","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2026.101534_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2024.108925","article-title":"Unraveling Interleukin-1\u03b2 inhibition: Computational insights into anti-inflammatory compound selection for inflammatory disorders","volume":"135","author":"Sardar","year":"2025","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.cytogfr.2026.101534_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.compbiolchem.2015.06.004","article-title":"silico identification of novel IL-1\u03b2 inhibitors to target protein\u2013protein interfaces","volume":"58","author":"Halim","year":"2015","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2026.101534_bib25","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.3390\/molecules28134885","article-title":"Silico Identification of Natural Product-Based Inhibitors Targeting IL-1\u03b2\/IL-1R Protein\u2013Protein Interface","volume":"28","author":"Liu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.cytogfr.2026.101534_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.137295","article-title":"Small molecule inhibitors of IL-1R1\/IL-1\u03b2 interaction identified via transfer machine learning QSAR modelling","volume":"282","author":"Pirzada","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40272-023-00615-5","article-title":"Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA)","volume":"26","author":"Cetin Gedik","year":"2024","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.cytogfr.2026.101534_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ncprheum0681","article-title":"Primer: inflammasomes and interleukin 1\u03b2 in inflammatory disorders","volume":"4","author":"Church","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00281-015-0491-7","article-title":"CAPS \u2014 pathogenesis, presentation and treatment of an autoinflammatory disease","volume":"37","author":"Kuemmerle-Deschner","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.autrev.2012.07.026","article-title":"Targeting interleukin-1\u03b2 in CAPS (cryopyrin-associated periodic) syndromes","volume":"12","author":"Kon\u00e9-Paut","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/cei.12361","article-title":"Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"177","author":"Haverkamp","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis","volume":"7","author":"Giancane","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib33","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2147\/DDDT.S114532","article-title":"The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives","volume":"12","author":"Toplak","year":"2018","journal-title":"Drug. Des. Devel. Ther."},{"key":"10.1016\/j.cytogfr.2026.101534_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12969-017-0147-3","article-title":"Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis","volume":"15","author":"H\u00fcgle","year":"2017","journal-title":"Pediatr. Rheumatol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2021.03.003","article-title":"Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease","volume":"60","author":"Song","year":"2021","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib36","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.3390\/ijms232112757","article-title":"Biomarkers in Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Their Importance in COVID Era","volume":"23","author":"Ailioaie","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2026.101534_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-016-1069-z","article-title":"Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?","volume":"18","author":"Gohar","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2026.101534_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-024-01993-x","article-title":"Adult-Onset Still\u2019s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options","volume":"84","author":"Bindoli","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.cytogfr.2026.101534_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211059598","article-title":"Update on the therapy of adult-onset Still\u2019s disease with a focus on IL-1-inhibition: a systematic review","volume":"13","author":"Kedor","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.cytogfr.2026.101534_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still\u2019s disease\u2014The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","volume":"47","author":"Junge","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cytogfr.2026.101534_bib41","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/art.27663","article-title":"How interleukin-1\u03b2 induces gouty arthritis","volume":"62","author":"Dinarello","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cytogfr.2026.101534_bib42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00281-013-0361-0","article-title":"Neutrophils, IL-1\u03b2, and gout: is there a link?","volume":"35","author":"Mitroulis","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib43","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2119\/molmed.2014.00232","article-title":"An Expanding Role for Interleukin-1 Blockade from Gout to Cancer","volume":"20","author":"Dinarello","year":"2014","journal-title":"Mol. Med."},{"key":"10.1016\/j.cytogfr.2026.101534_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","article-title":"Interleukin-1\u03b2 inhibitors for the management of acute gout flares: a systematic literature review","volume":"25","author":"Schlesinger","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2026.101534_bib45","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2026.101534_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1743-8977-10-39","article-title":"Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells","volume":"10","author":"Hillegass","year":"2013","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/089583798197736","article-title":"Contribution of human pulmonary macrophage-derived cytokines to asbestos-induced lung inflammation and fibrosis","volume":"10","author":"Ishihara","year":"1998","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00408-015-9744-4","article-title":"Inflammatory Cytokines Contribute to Asbestos-Induced Injury of Mesothelial Cells","volume":"193","author":"Acencio","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.cytogfr.2026.101534_bib49","first-page":"403","article-title":"The production of TNF-alpha and IL-1-like activity by bronchoalveolar leucocytes after intratracheal instillation of crocidolite asbestos","volume":"74","author":"Li","year":"1993","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib50","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1164\/ajrccm.157.5.9707141","article-title":"Mechanisms in the Pathogenesis of Asbestosis and Silicosis","volume":"157","author":"Mossman","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cytogfr.2026.101534_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.31083\/j.rcm2403077","article-title":"Novel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent Pericarditis","volume":"24","author":"Bonaventura","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.cytogfr.2026.101534_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/FJC.0000000000001435","article-title":"Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives","volume":"83","author":"Thomas","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14656566.2022.2054327","article-title":"Advances in pharmacotherapy for acute and recurrent pericarditis","volume":"23","author":"Vecchi\u00e9","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.cytogfr.2026.101534_bib54","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2026.101534_bib55","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/heartjnl-2020-318869","article-title":"Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis","volume":"107","author":"Imazio","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.cytogfr.2026.101534_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-020-00438-5","article-title":"Failure of anti Interleukin-1 \u03b2 monoclonal antibody in the treatment of recurrent pericarditis in two children","volume":"18","author":"Signa","year":"2020","journal-title":"Pediatr. Rheumatol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113017","article-title":"Recurrent pericarditis and interleukin (IL)-1 inhibitors","volume":"141","author":"Principi","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589654","article-title":"Targeting IL-1\u03b2 in the Treatment of Atherosclerosis","volume":"11","author":"Mai","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijms24010017","article-title":"The IL-1 Family and Its Role in Atherosclerosis","volume":"24","author":"Gonz\u00e1lez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2026.101534_bib60","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 Beta as a Target for Atherosclerosis Therapy","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib61","first-page":"951","article-title":"Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis","volume":"138","author":"Moyer","year":"1991","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2011.02.026","article-title":"Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice","volume":"216","author":"Bhaskar","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cytogfr.2026.101534_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.901616","article-title":"The role of interleukin-1\u03b2 in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"13","author":"Alfadul","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI200215318","article-title":"Glucose-induced \u03b2 cell production of IL-1\u03b2 contributes to glucotoxicity in human pancreatic islets","volume":"110","author":"Maedler","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cytogfr.2026.101534_bib65","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/jcm11051303","article-title":"IL-1\u03b2 Implications in Type 1 Diabetes Mellitus Progression: Systematic Review and Meta-Analysis","volume":"11","author":"Cano-Cano","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cytogfr.2026.101534_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161548","article-title":"Role of Pro-Inflammatory Cytokines and Biochemical Markers in the Pathogenesis of Type 1 Diabetes: Correlation with Age and Glycemic Condition in Diabetic Human Subjects","volume":"11","author":"Fatima","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.cytogfr.2026.101534_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrendo.2009.271","article-title":"Blockade of interleukin 1 in type 1 diabetes mellitus","volume":"6","author":"Mandrup-Poulsen","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib68","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1517\/14712590903136688","article-title":"Interleukin-1 beta targeted therapy for type 2 diabetes","volume":"9","author":"Maedler","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.cytogfr.2026.101534_bib69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12863-015-0165-4","article-title":"Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis","volume":"16","author":"Guo","year":"2015","journal-title":"BMC Genet."},{"key":"10.1016\/j.cytogfr.2026.101534_bib70","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1995-7645(13)60030-9","article-title":"Correlation between IL-1\u03b2, IL-1Ra gene polymorphism and occurrence of polycystic ovary syndrome infertility","volume":"6","author":"Xia","year":"2013","journal-title":"Asian Pac. J. Trop. Med."},{"key":"10.1016\/j.cytogfr.2026.101534_bib71","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00011-017-1045-3","article-title":"Association of IL-1\u03b2, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome","volume":"66","author":"Rashid","year":"2017","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.cytogfr.2026.101534_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6076274","article-title":"Association of IL-1\u03b2, IL-6, TNF-\u03b1, and TGF\u03b21 Gene Polymorphisms with Recurrent Spontaneous Abortion in Polycystic Ovary Syndrome","volume":"2020","author":"Alkhuriji","year":"2020","journal-title":"Dis. Markers"},{"key":"10.1016\/j.cytogfr.2026.101534_bib73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-2094-5-7","article-title":"The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective","volume":"5","author":"Shaftel","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.cytogfr.2026.101534_bib74","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.4049\/jimmunol.1100620","article-title":"Blocking IL-1 Signaling Rescues Cognition, Attenuates Tau Pathology, and Restores Neuronal \u03b2-Catenin Pathway Function in an Alzheimer\u2019s Disease Model","volume":"187","author":"Kitazawa","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib75","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-1331.2008.02252.x","article-title":"Cytokine IL-1 beta but not IL-1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain","volume":"15","author":"D\u00e9niz-Naranjo","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib76","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1159\/000255051","article-title":"Increased Serum IL-1\u03b2 Level in Alzheimer\u2019s Disease and Mild Cognitive Impairment","volume":"28","author":"Forlenza","year":"2009","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.cytogfr.2026.101534_bib77","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.4049\/jimmunol.1700263","article-title":"New Insights into the Role of IL-1\u03b2 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis","volume":"198","author":"Lin","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/0962933031000097691","article-title":"Interleukin (IL)-1 gene polymorphisms: relevance of disease severity associated alleles with IL-1\u03b2 and IL-1ra production in multiple sclerosis","volume":"12","author":"Schrijver","year":"2003","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.cytogfr.2026.101534_bib79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.11.004","article-title":"The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy","volume":"207","author":"Dujmovic","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0165-5728(02)00056-5","article-title":"Production of IL-1\u03b2 and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis","volume":"126","author":"De Jong","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib81","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0165-5728(00)00202-2","article-title":"Association of two variants in IL-1\u03b2 and IL-1 receptor antagonist genes with multiple sclerosis","volume":"106","author":"Kantarci","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cytogfr.2024.09.004","article-title":"Molecular mechanisms of regulation of IL-1 and its receptors","volume":"80","author":"Zhukova","year":"2024","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib83","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The Inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2026.101534_bib84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The Inflammasome","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell."},{"key":"10.1016\/j.cytogfr.2026.101534_bib85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cytogfr.2020.08.003","article-title":"Mechanisms of NLRP3 priming in inflammaging and age related diseases","volume":"55","author":"Gritsenko","year":"2020","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cytogfr.2025.05.005","article-title":"The secretion of interleukin-1\u03b2","volume":"84","author":"Ford","year":"2025","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib87","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.1074\/jbc.270.23.13757","article-title":"Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex","volume":"270","author":"Greenfeder","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2026.101534_bib88","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4172\/2161-0444.1000300","article-title":"Attempt to Explore the Binding Mechanism of IL-1\u03b2 Inhibitors via Molecular Docking Studies","volume":"5","author":"Halim","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.cytogfr.2026.101534_bib89","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nsmb.2260","article-title":"Structure of the activating IL-1 receptor signaling complex","volume":"19","author":"Thomas","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib90","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2026.101534_bib91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/BTT.S102954","article-title":"Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature","volume":"10","author":"van der Hilst","year":"2016","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/j.cytogfr.2026.101534_bib92","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/s41467-023-41190-0","article-title":"Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1\u03b2","volume":"14","author":"Hommel","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2026.101534_bib93","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1021\/acs.jctc.2c01189","article-title":"Accelerating Cryptic Pocket Discovery Using AlphaFold","volume":"19","author":"Meller","year":"2023","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.cytogfr.2026.101534_bib94","doi-asserted-by":"crossref","first-page":"11477","DOI":"10.1074\/jbc.270.19.11477","article-title":"Mapping Receptor Binding Sites in Interleukin (IL)-1 Receptor Antagonist and IL-1\u03b2 by Site-directed Mutagenesis","volume":"270","author":"Evans","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2026.101534_bib95","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/antiox11020294","article-title":"Assessment of Antioxidant, Immunomodulatory Activity of Oxidised Epigallocatechin-3-Gallate (Green Tea Polyphenol) and Its Action on the Main Protease of SARS-CoV-2\u2014An In Vitro and In Silico Approach","volume":"11","author":"Ungarala","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.cytogfr.2026.101534_bib96","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1080\/07391102.2024.2304669","article-title":"Identification of ZINC08101049 as a potential IL1\u03b2 inhibitor through molecular docking and MD simulations for cancer therapeutics","volume":"43","author":"Alshahrani","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.cytogfr.2026.101534_bib97","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/cimb47121039","article-title":"Advancing Drug Repurposing for Rheumatoid Arthritis: Integrating Protein\u2013Protein Interaction, Molecular Docking, and Dynamics Simulations for Targeted Therapeutic Approaches","volume":"47","author":"Akey","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib98","doi-asserted-by":"crossref","first-page":"S4731","DOI":"10.4103\/jpbs.jpbs_1235_24","article-title":"Computational Studies on Recent Congeners of Fluoroquinolones and Nitroimidazoles for Their Use in Periodontal Therapy","volume":"16","author":"Natarajan","year":"2024","journal-title":"J. Pharm. Bioallied Sci."},{"key":"10.1016\/j.cytogfr.2026.101534_bib99","first-page":"22","article-title":"Phytoconstituents of Cassia auriculata Linn Inhibits the Pro-Inflammatory Cytokines: An In Silico Study to Identify Multi-Target Drug Candidates","volume":"14","author":"Tejaswini","year":"2025","journal-title":"Lett. Appl. NanoBioScience"},{"key":"10.1016\/j.cytogfr.2026.101534_bib100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7324\/JAPS.2024.174125","article-title":"Chromatographical fingerprint analysis, in silico investigation, and identification of hepatoprotective active compounds from Capparis decidua Edgwe (Forssk.)","volume":"14","author":"Osman","year":"2024","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.cytogfr.2026.101534_bib101","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/biom10091337","article-title":"The Cytokine IL-1\u03b2 and Piperine Complex Surveyed by Experimental and Computational Molecular Biophysics","volume":"10","author":"Zazeri","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.cytogfr.2026.101534_bib102","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.48048\/tis.2024.8026","article-title":"Identification of Metabolite Compounds from A Ethanol Extract of Caulerpa racemosa using LC-MS\/MS with Inhibitory Activity of Interleukin-1\u03b2 and Expression Inhibitory Nitric Oxide Synthase Enzyme; In Silico Virtual Screening","volume":"21","author":"Prayogo","year":"2024","journal-title":"Trends Sci."},{"key":"10.1016\/j.cytogfr.2026.101534_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2022.107774","article-title":"Interface inhibitory action on Interleukin-1\u03b2 using selected anti-inflammatory compounds to mitigate the depression: A computational investigation","volume":"101","author":"Sardar","year":"2022","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2026.101534_bib104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12016-013-8358-y","article-title":"IL-1\u03b2 Biological Treatment of Familial Mediterranean Fever","volume":"45","author":"Soriano","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib105","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41467-023-36699-3","article-title":"Predicting locations of cryptic pockets from single protein structures using the PocketMiner graph neural network","volume":"14","author":"Meller","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2026.101534_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1731165","article-title":"Dapansutrile in multidisciplinary therapeutic applications: mechanisms and clinical perspectives","volume":"16","author":"Bai","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib107","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13789","article-title":"First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor","volume":"17","author":"Gatlik","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.cytogfr.2026.101534_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.cytogfr.2026.101534_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.09.007","article-title":"Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors","volume":"74","author":"Ye","year":"2023","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.101534_bib110","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/03008207.2025.2520319","article-title":"Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions","volume":"66","author":"Peitso","year":"2025","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.cytogfr.2026.101534_bib111","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.ymthe.2025.09.008","article-title":"Nature-inspired IL-1 targeted therapy to treat chronic inflammatory diseases","volume":"33","author":"Yang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cytogfr.2026.101534_bib112","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/pharmaceutics14091785","article-title":"Anti-Inflammatory Therapy for Temporomandibular Joint Osteoarthritis Using mRNA Medicine Encoding Interleukin-1 Receptor Antagonist","volume":"14","author":"Deng","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cytogfr.2026.101534_bib113","doi-asserted-by":"crossref","first-page":"eabj1414","DOI":"10.1126\/sciadv.abj1414","article-title":"A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery","volume":"7","author":"Choi","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cytogfr.2026.101534_bib114","article-title":"Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib115","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jmb.2016.01.029","article-title":"CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites","volume":"428","author":"Cimermancic","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib116","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/acs.accounts.9b00613","article-title":"Investigating Cryptic Binding Sites by Molecular Dynamics Simulations","volume":"53","author":"Kuzmanic","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.cytogfr.2026.101534_bib117","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbagen.2014.10.019","article-title":"Enhanced sampling techniques in molecular dynamics simulations of biological systems","volume":"1850","author":"Bernardi","year":"2015","journal-title":"Biochim. Biophys. Acta BBA - Gen. Subj."},{"key":"10.1016\/j.cytogfr.2026.101534_bib118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/prot.26002","article-title":"Molecular dynamics analysis of the binding of human interleukin-6 with interleukin-6 \u03b1-receptor","volume":"89","author":"Gupta","year":"2021","journal-title":"Proteins"},{"key":"10.1016\/j.cytogfr.2026.101534_bib119","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.cytogfr.2026.101534_bib120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.cytogfr.2026.101534_bib121","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012600081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012600081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:12:44Z","timestamp":1792167164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135961012600081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":121,"alternative-id":["S135961012600081X"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.101534","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-1\u03b2 as a central driver of inflammation: Mechanistic insight into activation, receptor signaling, and therapeutic inhibition","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.101534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101534"}}